Profund Advisors LLC Biotechnology

Profund Advisors LLC

$2.59 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
PRTA Prothena Corp Public LTD CO	$641M	$211,000 0.01% of portfolio	12,661	Q3 2024 Reduced 29.95%
SAGE Sage Therapeutics, Inc.	$323M	$211,000 0.01% of portfolio	29,348	Q3 2024 Added 27.83%
ANNX Annexon, Inc.	$244M	$209,000 0.01% of portfolio	35,447	Q3 2024 New
TECH Bio Techne Corp	$2.83B	$208,000 0.01% of portfolio	2,611	Q3 2024 New
STOK Stoke Therapeutics, Inc.	$435M	$201,000 0.01% of portfolio	16,401	Q3 2024 Added 10.13%
VERV Verve Therapeutics, Inc.	$338M	$200,000 0.01% of portfolio	41,391	Q3 2024 Added 48.28%
FDMT 4 D Molecular Therapeutics, Inc.	$180M	$196,000 0.01% of portfolio	18,142	Q3 2024 Added 1.0%
OCUL Ocular Therapeutix, Inc	$657M	$194,000 0.01% of portfolio	22,357	Q3 2024 Reduced 48.23%
ETNB 89bio, Inc.	$357M	$191,000 0.01% of portfolio	25,843	Q3 2024 Reduced 4.64%
ALT Altimmune, Inc.	$353M	$190,000 0.01% of portfolio	30,954	Q3 2024 Reduced 24.06%
SRRK Scholar Rock Holding Corp	$2.23B	$186,000 0.01% of portfolio	23,312	Q3 2024 Reduced 6.68%
RGNX Regenxbio Inc.	$334M	$176,000 0.01% of portfolio	16,858	Q3 2024 Reduced 18.19%
ALLO Allogene Therapeutics, Inc.	$306M	$175,000 0.01% of portfolio	62,634	Q3 2024 Reduced 17.76%
CELC Celcuity Inc.	$196M	$167,000 0.01% of portfolio	11,267	Q3 2024 New
CCCC C4 Therapeutics, Inc.	$176M	$162,000 0.01% of portfolio	28,436	Q3 2024 Reduced 16.73%
AVXL Anavex Life Sciences Corp.	$837M	$158,000 0.01% of portfolio	27,973	Q3 2024 Reduced 32.24%
TNGX Tango Therapeutics, Inc.	$272M	$157,000 0.01% of portfolio	20,473	Q3 2024 Added 47.36%
OCGN Ocugen, Inc.	$173M	$154,000 0.01% of portfolio	156,167	Q3 2024 Added 6.5%
FATE Fate Therapeutics Inc	$160M	$149,000 0.01% of portfolio	42,652	Q3 2024 Reduced 8.33%
SVRA Savara Inc	$350M	$145,000 0.01% of portfolio	34,215	Q3 2024 Added 31.51%
MDXG Mimedx Group, Inc.	$1.09B	$138,000 0.01% of portfolio	23,516	Q3 2024 Reduced 12.56%
ORIC Oric Pharmaceuticals, Inc.	$319M	$138,000 0.01% of portfolio	13,502	Q3 2024 Reduced 38.24%
ERAS Erasca, Inc.	$307M	$130,000 0.01% of portfolio	47,626	Q3 2024 New
LQDA Liquidia Corp	$757M	$129,000 0.0% of portfolio	12,942	Q3 2024 Reduced 10.34%
FULC Fulcrum Therapeutics, Inc.	$245M	$124,000 0.0% of portfolio	34,846	Q3 2024 Added 219.07%
ATXS Astria Therapeutics, Inc.	$138M	$121,000 0.0% of portfolio	11,038	Q3 2024 Reduced 45.89%
PLRX Pliant Therapeutics, Inc.	$641M	$112,000 0.0% of portfolio	10,077	Q3 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$254M	$103,000 0.0% of portfolio	12,909	Q3 2024 Added 0.91%
WVE Wave Life Sciences Ltd.	$1.07B	$97,000 0.0% of portfolio	11,904	Q3 2024 Added 12.04%
ABUS Arbutus Biopharma Corp	$490M	$95,000 0.0% of portfolio	24,812	Q3 2024 New
ALEC Alector, Inc.	$156M	$72,000 0.0% of portfolio	15,450	Q3 2024 Reduced 20.67%
NUVB Nuvation Bio Inc.	$578M	$72,000 0.0% of portfolio	31,415	Q3 2024 Added 44.64%
XERS Xeris Biopharma Holdings, Inc.	$461M	$64,000 0.0% of portfolio	22,742	Q3 2024 Reduced 8.0%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	16,403	Q3 2024 Added 1.7%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.